Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Xamoterol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 known ✓ | P08588 | 18/20 | 1.00 |
| ▸ | ADRB3 | P13945 | 17/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 8/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.89 |
| ▸ | MAPT | P10636 | 1/20 | 0.89 |
| ▸ | BLM | P54132 | 1/20 | 0.89 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Xamoterol SCHEMBL11533496 | 1.00 | ADRB1 (1.00) | ADRB1ADRB3ADRB2LMNANFKB1 | |
| Xamoterol SCHEMBL30897538 | 1.00 | ADRB1 (1.00) | ADRB1ADRB3ADRB2LMNANFKB1 | |
| Xamoterol SCHEMBL3702016 | 0.99 | ADRB1 (0.98) | ADRB1ADRB3ADRB2LMNANFKB1 | |
| Xamoterol SCHEMBL3697718 | 0.99 | ADRB1 (0.98) | ADRB1ADRB3ADRB2LMNANFKB1 | |
| Xamoterol SCHEMBL122201 | 0.94 | ADRB2 (1.00) | ADRB1ADRB3ADRB2LMNANFKB1 | |
| Xamoterol SCHEMBL1651584 | 0.94 | ADRB2 (1.00) | ADRB1ADRB3ADRB2LMNANFKB1 | |
| Xamoterol SCHEMBL10584728 | 0.94 | ADRB2 (1.00) | ADRB1ADRB3ADRB2LMNANFKB1 | |
| Xamoterol SCHEMBL3695282 | 0.94 | ADRB2 (1.00) | ADRB1ADRB3ADRB2LMNANFKB1 | |
| SCHEMBL22279241 | 0.90 | ADRB1 (0.82) | ADRB1ADRB3ADRB2LMNANFKB1 | |
| SCHEMBL22278959 | 0.90 | ADRB1 (0.82) | ADRB1ADRB3ADRB2LMNANFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 5949 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12529704-B2 | Methods for objective assessment of stress, early detection of risk for stress disorders, matching individuals with treatments, monitoring response to treatment, and new methods of use for drugs | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2026-01-20 | — | — | US | claimed |
| WO-2025265094-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-12-26 | — | — | WO | claimed |
| US-20250213647-A1 | CHEMOKINE RECEPTORS AND ALPHA1 ADRENERGIC RECEPTORS/VASOPRESSIN RECEPTORS 1A HETEROMERS AS DRUG TARGETS FOR DISEASE | UNIVERSITY OF SOUTH FLORIDA | 2025-07-03 | — | — | US | claimed |
| CN-119233997-A | Tetrahedral antibodies | 生物分子控股有限责任公司 | 2024-12-31 | — | — | CN | claimed |
| US-20240398729-A1 | Methods and Compositions for the Treatment of Cytoplasmic Glycogen Storage Disorders | DUKE UNIVERSITY (US) | 2024-12-05 | — | — | US | claimed |
| EP-4463485-A2 | TETRAHEDRAL ANTIBODIES | Biomolecular Holdings LLC (US) | 2024-11-20 | — | — | EP | claimed |
| US-20240366586-A1 | METHODS AND AGENTS FOR MODULATING THE IMMUNE RESPONSE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-11-07 | — | — | US | claimed |
| CN-118384290-A | Hybrid immunoglobulins containing non-peptide linkages | 生物分子控股有限责任公司 | 2024-07-26 | — | — | CN | claimed |
| US-20230420110-A1 | METHODS FOR OBJECTIVE ASSESSMENT, RISK PREDICTION, MATCHING TO EXISTING MEDICATIONS AND NEW METHODS OF USING DRUGS, AND MONITORING RESPONSES TO TREATMENTS FOR MOOD DISORDERS | UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2023-12-28 | — | — | US | claimed |
| WO-2023192319-A1 | CHEMOKINE RECEPTORS AND ALPHA1 ADRENERGIC RECEPTORS/VASOPRESSIN RECEPTORS 1A HETEROMERS AS DRUG TARGETS FOR DISEASE | UNIVERSITY OF SOUTH FLORIDA (US) | 2023-10-05 | — | — | WO | claimed |
| EP-0534706-A1 | Quinazolinones and pyridopyrimidinones useful as angiotensin II antagonists | MERCK & CO. INC. (US) | 1993-03-31 | — | — | EP | claimed |
| EP-0366765-A4 | ANTIGLAUCOMA COMPOSITIONS CONTAINING COMBINATIONS OF SYMPATHOMIMETIC AGENTS AND BETA-1 SELECTIVE BETA-BLOCKERS | — | 1990-12-05 | — | — | EP | claimed |
| US-4933340-A | N-(2-(RS-2-HYDROXY-3-(4-HYDROXYPHENOXY)PROPYLAMINO) ETHYL)-MORPHOLINOFORMAMIDE | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-06-12 | — | — | US | claimed |
| EP-0366765-A1 | ANTIGLAUCOMA COMPOSITIONS CONTAINING COMBINATIONS OF SYMPATHOMIMETIC AGENTS AND BETA-1 SELECTIVE BETA-BLOCKERS. | ALCON LAB INC (US) | 1990-05-09 | — | — | EP | claimed |
| US-4880805-A | CARDIOVASCULAR DISORDERS | BOEHRINGER MANNHEIM GMBH (DE) | 1989-11-14 | — | — | US | claimed |
| WO-1989010120-A1 | ANTIGLAUCOMA COMPOSITIONS CONTAINING COMBINATIONS OF SYMPATHOMIMETIC AGENTS AND BETA-1 SELECTIVE BETA-BLOCKERS | ALCON LABORATORIES, INC. (US) | 1989-11-02 | — | — | WO | claimed |
| EP-0307115-A1 | Phenol esters | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1989-03-15 | — | — | EP | claimed |
| EP-0227339-A2 | Xamoterol for the treatment of obesity | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-07-01 | — | — | EP | claimed |
| EP-0172446-A2 | Utilisation of alkylenediamine derivatives for the treatment of irrigation troubles, and medicaments containing these compounds | Roche Diagnostics GmbH (DE) | 1986-02-26 | — | — | EP | claimed |
| US-4143140-A | CARDIO-SELECTIVE B-ADRENERGIC STIMULANT; 1-HYDROXYPHENOXY-3-UREIDOETHYLAMINO-2-PROPANOL DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1979-03-06 | — | — | US | claimed |